Prime Medicine, Inc. PRME
2.90
(0.17)
(5.54%)
as of 25 Sep
- Market cap
- $609.4M
- P/E
- 0.0×
Follow PRME
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (373.29%) | (216.07%) | (146.81%) | (112.34%) |
+8 more TTM periods Free account |
|
| (71.16%) | (63.69%) | (62.83%) | (54.98%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(228.61%) | (164.74%) | (122.34%) | (90.34%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.88) | (0.90) | (1.12) | (0.72) | |
Free Cash Flow |
(156.85) | (158.74) | (167.09) | (115.09) | |
Capital Expenditures |
(0.80) | (2.32) | (4.53) | (6.03) | |
Piotroski F-Score |
2.00 | 1.00 | 4.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(115.70%) | (73.71%) | (54.45%) | (29.08%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
3,589.52% | 3,821.99% | 3,467.96% | 2,677.45% | |
Selling, General and Administrative Expense of Revenue |
1,335.43% | 1,399.78% | 1,130.09% | 835.03% | |
Share Based Compensation of Revenue |
657.28% | 699.83% | 631.87% | 513.54% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.83 | 0.79 | 0.81 | 0.55 | |
Depreciation/Fixed assets |
0.31 | 0.28 | 0.26 | 0.27 | |
Capex/Depreciation |
(0.15) | (0.44) | (0.84) | (1.03) | |
Revenue per Share |
0.02 | 0.02 | 0.03 | 0.04 | |
Operating CF per Share |
(0.88) | (0.88) | (1.09) | (0.68) | |
Capex per Share |
0.00 | (0.01) | (0.03) | (0.04) | |
Capex to Sales |
0.20 | 0.58 | 0.98 | 1.01 | |
Net Profit Margin |
(4,613.11%) | (4,917.55%) | (4,342.44%) | (3,301.64%) |
Columns are period end dates